Oxford BioMedica (OTCMKTS:OXBDF) Lifted to “Hold” at Zacks Investment Research

Zacks Investment Research upgraded shares of Oxford BioMedica (OTCMKTS:OXBDF) from a sell rating to a hold rating in a research report sent to investors on Wednesday, Zacks.com reports.

According to Zacks, “Oxford BioMedica Plc is a gene and cell therapy company which focused on developing life changing treatments for serious diseases. Oxford BioMedica Plc is headquartered in Oxford, the United Kingdom. “

Separately, HC Wainwright reissued a buy rating and issued a $14.50 target price on shares of Oxford BioMedica in a report on Tuesday, May 28th.

Oxford BioMedica stock opened at $7.85 on Wednesday. The firm has a 50 day moving average of $8.70 and a 200 day moving average of $8.94. The firm has a market capitalization of $535.26 million, a price-to-earnings ratio of 52.33 and a beta of 0.74. Oxford BioMedica has a 12-month low of $7.85 and a 12-month high of $12.20.

Oxford BioMedica Company Profile

Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments.

Recommended Story: Google Finance Portfolio

Get a free copy of the Zacks research report on Oxford BioMedica (OXBDF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.